AhR Inhibitors
1 drugsAbout AhR
The Aryl hydrocarbon receptor (AhR) is a ligand-activated transcription factor mediating the effects of environmental contaminants and endogenous compounds, influencing cellular processes.
AhR has therapeutic potential in immunology, as evidenced by the FDA-approved drug VTAMA, though no genetic evidence directly links AhR to specific diseases.
AhR is currently targeted by one FDA-approved drug, VTAMA (Merck), a small molecule used in immunology.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Palmoplantar Keratoderma with only 1 trials.
Top AhR Drugs
Merck is the only company with an approved drug targeting AhR.
The lack of competitors suggests high barriers to entry or untapped market potential.
AhR Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets AhR, using small molecule modality.
Exploring alternative modalities like antibodies or peptides could provide differentiation.
AhR Clinical Trials 19 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 1 | 1 | 0 | 0 | 100% |
| Phase 2 | 4 | 2 | 0 | 1 | 100% |
| Phase 3 | 9 | 7 | 0 | 2 | 100% |
| Phase 4 | 5 | 3 | 0 | 2 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
AhR Drug Approval Timeline (2022 - 2022)
The first and only drug targeting AhR, VTAMA, was approved in 2022.
The recent approval suggests a renewed interest in AhR as a drug target.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 26 clinical trials targeting AhR.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities